Last reviewed · How we verify

hUCB — Competitive Intelligence Brief

hUCB (hUCB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allogeneic hematopoietic stem cell therapy. Area: Oncology / Hematology.

marketed Allogeneic hematopoietic stem cell therapy Oncology / Hematology Biologic Live · refreshed every 30 min

Target snapshot

hUCB (hUCB) — StemCyte Taiwan Co., Ltd.. hUCB is a human umbilical cord blood-derived cell therapy that provides hematopoietic and immunomodulatory support for hematologic reconstitution and immune recovery.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
hUCB TARGET hUCB StemCyte Taiwan Co., Ltd. marketed Allogeneic hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allogeneic hematopoietic stem cell therapy class)

  1. StemCyte Taiwan Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). hUCB — Competitive Intelligence Brief. https://druglandscape.com/ci/hucb. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: